You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Profs. Felix Mahfoud, Roland Schmieder, and Flavio Ribichini discuss key findings on RDN, including a 26% relative risk reduction in cardiovascular events.*1
VISIT WONDR MEDICALWatch interviews with experts on the latest data in RDN from TCT Connect 2020.
A Pivotal Moment for RDN - (12:04)
Dr. David Kandzari discusses primary results from the SPYRAL HTN-OFF MED Pivotal Trial.
More information (see more)
Less information (see less)
Data and Science Revisited - (12:47)
Dr. Flavio Ribichini recaps the history and scientific basis behind renal denervation.
More information (see more)
Less information (see less)
Real-World Experience of RDN - (11:08)
Prof. Markus Schlaich discusses safety, efficacy and patient selection insights from the largest study of renal denervation.
More information (see more)
Less information (see less)
Clinical Case Discussion - (28:15)
Dr. Roland Schmieder and Dr. TD Wang discuss an actual RDN case as well as the related issues of non-adherence and patient preference.
More information (see more)
Less information (see less)
Used with permission from TCT Connect 2020.
Dr. Konstantinos Tsioufis and Dr. Michael Böhm present the clinical results from the SPYRAL HTN-OFF MED Pivotal trial.
Advances in the Renal Denervation Procedure - (20:13)
Medtronic 2020 PCR e-Course video covering advances in renal denervation (RDN) for hypertension procedures.
More information (see more)
Less information (see less)
Renal Denervation: Putting Guidelines into Practice - (15:17)
Medtronic 2020 PCR e-Course video about putting guidelines into practice around renal denervation (RDN) for hypertension.
More information (see more)
Less information (see less)
Blood Pressure Outcomes: Renal Denervation in Various Patient Subgroups - (06:45)
Medtronic 2020 PCR e-Course video covering blood pressure outcomes around renal denervation (RDN) for hypertension in various patient subgroups.
More information (see more)
Less information (see less)
Addressing the Population Question: Interesting Case Profiles in Renal Denervation - (15:52)
Used with permission from PCROnline 2020.
If you missed our online late- breaking presentation on SPYRAL HTN-OFF MED Pivotal data, you can watch it now.
See clinical studies that evaluate the safety and efficacy of the Symplicity™ Spyral RDN system.
REVIEW CLINICAL STUDIESRead guidelines for ideal RDN candidates from around the world.
EXPLORE PATIENT SELECTIONFor patients in the GLOBAL SYMPLICITY REGISTRY, compared to a modeled control group.
Schmieder R, Böhm M, Schlaich M, et al. Modeled Clinical Event Reductions at Three Years in High-Risk Hypertension Patients Treated with Renal Denervation. Presented at Deutsche Gesellschaft fur Kardiologie 2021.
Disclaimer: This page may include information about products that may not be available in your region or country. Please consult the approved indications for use. Content on specific Medtronic products is not intended for users in markets that do not have authorization for use.